• Jeffrey J Swigris, Kevin K Brown, Rayid Abdulqawi, Ketan Buch, Daniel F Dilling, Dirk Koschel, Krishna Thavarajah, Rade Tomic, and Yoshikazu Inoue.
• Interstitial Lung Disease Program, National Jewish Health, Denver, CO, USA.
• Eur Respir Rev. 2018 Dec 31; 27 (150).

AbstractThe effects of interstitial lung disease (ILD) create a significant burden on patients, unsettling almost every domain of their lives, disrupting their physical and emotional well-being and impairing their quality of life (QoL). Because many ILDs are incurable, and there are limited reliably-effective, life-prolonging treatment options available, the focus of many therapeutic interventions has been on improving or maintaining how patients with ILD feel and function, and by extension, their QoL. Such patient-centred outcomes are best assessed by patients themselves through tools that capture their perceptions, which inherently incorporate their values and judgements. These patient-reported outcome measures (PROs) can be used to assess an array of constructs affected by a disease or the interventions implemented to treat it. Here, we review the impact of ILD that may present with a progressive-fibrosing phenotype on patients' lives and examine how PROs have been used to measure that impact and the effectiveness of therapeutic interventions.Copyright ©ERS 2018.

28 keywords...

hide…